

Company Name: Linical Co., Ltd.

Representative: Kazuhiro Hatano

President & CEO (TSE code: 2183)

April 26, 2024

Notice of Appointment of Board of Directors and Introduction of New

Management Structure

Linical Co., Ltd. (the "Company") hereby announces that the Board of Directors meeting held today resolved to appoint Executive Directors and introduce the CXOs (Chief X Officers) system as follows.

At the Board of Directors meeting scheduled for July 31, 2023, the Company resolved to appoint a part of the current directors (excluding directors who serve as audit committee members and external directors) as executive officers after the 19th Ordinary General Meeting of Shareholders, which is scheduled to be held in June 2024. The resolution aims to ensure that the majority of the Board of Directors will be Outside Directors, and the ratio of female Directors will be 30% or more. Accordingly, the Company resolved today to elect candidates for Executive Directors and introduce a CXOs system.

 Candidates for Executive Directors (excluding Executive Directors who are Audit and Supervisory Committee Members)

(To be submitted to the 19th Ordinary General Meeting of Shareholders to be held in June 2024)

Name	New position	Current position
Kazuhiro Hatano	Representative Director	Same as on the left
Eri Sugiyama (Note)	Outside Executive Director	Same as on the left
Satoko Nishimura	Outside Executive Director	Same as on the left

(Note) Her name on the family register is Eri Shingu.

2. Candidate for Substitute Executive Director (excluding Executive Directors who are Audit and Supervisory Committee Members)

(To be submitted to the 19th Ordinary General Meeting of Shareholders to be held in June 2024)

Name	New position	Current position
Isao Sakamoto	Substitute Executive Director	Executive Director

3. Candidate for Substitute Executive Director who is Audit and Supervisory Committee Member (To be submitted to the 19th Ordinary General Meeting of Shareholders to be held in June 2024)

Name	New position	Current position
Hiroshige Matsuhisa	Substitute Audit and Supervisory Committee Member (Substitute Outside Executive Director)	-

Professional background of Hiroshige Matsuhisa

_	·
April 1975	Joined Fujisawa Pharmaceutical Co., Ltd. (currently Astellas Pharma Inc.)
October 1998	Deputy Director of Human Resources Department of Fujisawa Pharmaceutical
	Co., Ltd. and Director of Progrowth
April 2002	Head of Production and General Affairs Department of Fujisawa Pharmaceutical
	Co., Ltd.
April 2005	Senior Director, Strategy & Administration Technology and Head of Kashima
	Operation of Astellas Pharma Inc.
June 2013	Director, Head Office of The Research Foundation for Microbial Diseases of Osaka
	University
May 2017	Director of BIKEN Co., Ltd.
June 2023	Advisor of The Research Foundation for Microbial Diseases of Osaka University
	(current position)

^{*}Current Executive Directors who are Audit and Supervisory Committee Members:

Name	Current position
Yoshiaki Nakashima	Full-time Audit and Supervisory Committee Member (Outside Executive Director)
Yuichi Murakami	Full-time Audit and Supervisory Committee Member (Outside Executive Director)
Yoshimitsu Ando	Full-time Audit and Supervisory Committee Member (Outside Executive Director)

4. New Management Structure (As of June 26, 2024)

1) Outline

The newly established CXOs will be responsible for executing tasks in cross-functional areas on a global basis, including overseas subsidiaries, under the authority delegated by the Representative Director and President.

By advancing the separation of management and execution, the Company aims to strengthen corporate governance and enhance the management foundation to support the rapidly expanding global business. This will lead to sustainable growth and improvement in corporate value.

2) Appointment of CXOs

Name	New position
Kazuhiro Hatano	President & CEO,
	concurrently CCO (Global Chief Commercial Officer)
Isao Sakamoto	CSO (Global Chief Strategy Officer)

Jun Kawai	CAO (Global Chief Administrative Officer)
Akihiro Takahashi	CFO (Global Chief Financial Officer)
Shiori Yamaguchi	CCO (Global Chief Compliance Officer)
Masayoshi Tokuno	CIO (Global Chief Information Officer)
Keigo Tsujimoto	CPO (Global Chief Project Officer)
Masaya Miyazaki	CAPO (Chief Asia Pacific Officer)
Toshiaki Nagafuji	CTO (Global Chief Technical Officer)

Notes: This is a translation of the press release originally drafted in Japanese for the disclosure required in compliance with the TSE regulations.